X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (102) 102
male (62) 62
female (59) 59
hematology (58) 58
adult (54) 54
index medicus (54) 54
middle aged (54) 54
aged (49) 49
oncology (42) 42
cancer (26) 26
adolescent (20) 20
chemotherapy (20) 20
lymphoma (19) 19
aged, 80 and over (17) 17
multiple myeloma (17) 17
multiple myeloma - drug therapy (17) 17
bortezomib (16) 16
lymphomas (16) 16
therapy (15) 15
recurrence (14) 14
survival (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
patients (13) 13
retrospective studies (13) 13
abridged index medicus (12) 12
antineoplastic agents - adverse effects (12) 12
antineoplastic agents - therapeutic use (12) 12
disease-free survival (12) 12
leukemia (12) 12
treatment outcome (12) 12
analysis (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (11) 11
dexamethasone (11) 11
disease progression (11) 11
prognosis (11) 11
risk factors (11) 11
care and treatment (10) 10
expression (10) 10
medicine, general & internal (10) 10
young adult (10) 10
apoptosis (9) 9
clinical trials (9) 9
disease (9) 9
gene (9) 9
genetics & heredity (9) 9
kaplan-meier estimate (9) 9
leukemia, myelogenous, chronic, bcr-abl positive - genetics (9) 9
multiple myeloma - mortality (9) 9
risk (9) 9
transplantation (9) 9
animals (8) 8
antineoplastic agents - administration & dosage (8) 8
biochemistry (8) 8
chemistry (8) 8
chronic myelogenous leukemia (8) 8
diagnosis (8) 8
follow-up studies (8) 8
metallurgy (8) 8
minimal residual disease (8) 8
polymerase chain reaction (8) 8
research (8) 8
survival analysis (8) 8
thalidomide (8) 8
thalidomide - administration & dosage (8) 8
thalidomide - analogs & derivatives (8) 8
cell biology (7) 7
dna methylation (7) 7
drug therapy (7) 7
lenalidomide (7) 7
medicine & public health (7) 7
microbiology (7) 7
microsatellite instability (7) 7
non-hodgkin lymphoma (7) 7
non-hodgkin's lymphomas (7) 7
acute myeloid-leukemia (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
beer (6) 6
boronic acids - adverse effects (6) 6
dexamethasone - administration & dosage (6) 6
drug resistance, neoplasm (6) 6
enzymology (6) 6
follicular lymphoma (6) 6
fusion proteins, bcr-abl - genetics (6) 6
genetic aspects (6) 6
health aspects (6) 6
health risk assessment (6) 6
medical prognosis (6) 6
multicenter (6) 6
mutation or genetic engineering (6) 6
neutropenia (6) 6
prednisone - administration & dosage (6) 6
prednisone - adverse effects (6) 6
pyrazines - adverse effects (6) 6
remission induction (6) 6
research article (6) 6
rituximab (6) 6
signal transduction (6) 6
spirits (6) 6
survival rate (6) 6
vinegar (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 2, pp. 142 - 152
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2016, Volume 375, Issue 14, pp. 1319 - 1331
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 10, pp. 895 - 905
In patients 65 or younger with multiple myeloma, high-dose consolidation therapy was associated with longer survival and more myelotoxicity than... 
MEDICINE, GENERAL & INTERNAL | PREDNISONE | PLUS DEXAMETHASONE | INDUCTION THERAPY | LENALIDOMIDE | INITIAL TREATMENT | RANDOMIZED CONTROLLED-TRIAL | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Transplantation, Autologous | Consolidation Chemotherapy | Antineoplastic Agents, Alkylating - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Adult | Maintenance Chemotherapy | Neutropenia - chemically induced | Thalidomide - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Aged | Antineoplastic Agents, Alkylating - adverse effects | Stem Cell Transplantation - adverse effects | Complications and side effects | Care and treatment | Patient outcomes | Multiple myeloma | Stem cells | Transplantation | Research | Health aspects | Autografts | Chemotherapy | Cell survival | Transplants & implants | Melphalan | Stem cell transplantation | Death | Prednisone | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2016, Volume 374, Issue 17, pp. 1621 - 1634
The addition of the oral proteasome inhibitor ixazomib to a regimen of lenalidomide plus dexamethasone led to a significant prolongation of progression-free... 
SUPERIORITY | MEDICINE, GENERAL & INTERNAL | CARFILZOMIB | RANDOMIZED PHASE-3 | THERAPY | PROTEASOME INHIBITOR MLN9708 | QUALITY-OF-LIFE | BORTEZOMIB | THALIDOMIDE | ANTITUMOR-ACTIVITY | TRANSPLANTATION | Glycine - analogs & derivatives | Glycine - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Boron Compounds - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Exanthema - chemically induced | Aged, 80 and over | Adult | Glycine - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Administration, Oral | Kaplan-Meier Estimate | Proportional Hazards Models | Thrombocytopenia - chemically induced | Thalidomide - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Boron Compounds - adverse effects | Aged | Care and treatment | Dosage and administration | Dexamethasone | Multiple myeloma | Thrombocytopenia | Inhibitor drugs | Risk groups | Drug therapy | Peripheral neuropathy | Survival | Patients | Drug dosages | Proteasome inhibitors | Quality of life | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 19, pp. 1759 - 1769
Journal Article
by Experts in Chronic Myeloid Leukemia, in Chronic Myeloid Leukemia and Abboud, Camille and Berman, Ellin and Cohen, Adam and Cortes, Jorge and DeAngelo, Daniel and Deininger, Michael and Devine, Steven and Druker, Brian and Fathi, Amir and Jabbour, Elias and Jagasia, Madan and Kantarjian, Hagop and Khoury, Jean and Laneuville, Pierre and Larson, Richard and Lipton, Jeffrey and Moore, Joseph O and Mughal, Tariq and O'Brien, Susan and Pinilla-Ibarz, Javier and Quintas-Cardama, Alfonso and Radich, Jerald and Reddy, Vishnu and Schiffer, Charles and Shah, Neil and Shami, Paul and Silver, Richard T and Snyder, David and Stone, Richard and Talpaz, Moshe and Tefferi, Ayalew and Van Etten, Richard A and Wetzler, Meir and Abruzzese, Elisabetta and Apperley, Jane and Breccia, Massimo and Byrne, Jenny and Cervantes, Francisco and Chelysheva, Ekaterina and Clark, R.E and De Lavallade, Hugues and Dyagil, Iryna and Gambacorti-Passerini, Carlo and Goldman, John and Haznedaroglu, Ibrahim and Hjorth-Hansen, Henrik and Holyoake, Tessa and Huntly, Brian and Le Coutre, Philipp and Lomaia, Elza and Mahon, Francois-Xavier and Marin-Costa, David and Martinelli, Giovanni and Mayer, Jiri and Milojkovic, Dragana and Olavarria, Eduardo and Porkka, Kimmo and Richter, Johan and Rousselot, Philippe and Saglio, Giuseppe and Saydam, Guray and Stentoft, Jesper and Turkina, Anna and Vigneri, Paolo and Zaritskey, Andrey and Aguayo, Alvaro and Ayala, Manuel and Bendit, Israel and Bengio, Raquel Maria and Best, Carlos and Bullorsky, Eduardo and Cervera, Eduardo and Desouza, Carmino and Fanilla, Ernesto and Gomez-Almaguer, David and Hamerschlak, Nelson and Lopez, Jose and Magarinos, Alicia and Meillon, Luis and Milone, Jorge and Moiraghi, Beatriz and Pasquini, Ricardo and Pavlovsky, Carolina and Ruiz-Arguelles, Guillermo J and Spector, Nelson and Arthur, Christopher and Browett, Peter and Grigg, Andrew and Hu, Jianda and Huang, Xiao-jun and Hughes, Tim and Jiang, Qian and Jootar, Saengsuree and Kim, Dong-Wook and Malhotra, Hemant and Malhotra, Pankaj and Matsumura, Itaru and Melo, Junia and Ohnishi, Kazunori and ... and Experts Chronic Myeloid Leukemia and Experts in Chronic Myeloid Leukemia
Blood, ISSN 0006-4971, 05/2013, Volume 121, Issue 22, pp. 4439 - 4442
Journal Article